Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome–Negative Myeloproliferative Neoplasms

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis

(2010) S. Verstovsek   CLINICAL CANCER RESEARCH

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

(2010) A Tefferi   LEUKEMIA

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines

(2009) A. Jedidi et al.   BLOOD

How I treat symptomatic splenomegaly in patients with myelofibrosis

(2009) R. A. Mesa   BLOOD

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

(2009) P. Guglielmelli et al.   BLOOD

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

(2009) F. P. S. Santos et al.   BLOOD

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

(2008) A Tefferi et al.   LEUKEMIA